Literature DB >> 8611676

Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1.

A A Higazi1, A Mazar, J Wang, R Reilly, J Henkin, D Kniss, D Cines.   

Abstract

Urokinase-type plasminogen activator (uPA) is synthesized as single-chain protein (scuPA) with little intrinsic activity. scuPA is activated when it is converted to two-chain urokinase (tcuPA) by plasmin or when it binds as a single-chain molecule to its cellular receptor (uPAR). Previous data indicate that complexes between scuPA and its receptor have somewhat higher affinity for plasminogen than does tcuPA. The current study indicates that plasminogen activator activity of scuPA bound to recombinant, soluble uPAR (suPAR) is also fivefold less sensitive to inhibition by plasminogen activator type 1 (PAI-1) than is soluble or receptor-bound tcuPA. Binding of PaI-1 to suPAR/scuPA complexes is totally reversible and can be overcome by increasing the concentration of plasminogen, suggesting a competitive mechanism of inhibition (Ki = 18 nmol/L). Binding of scuPA to suPAR also retards its cleavage by plasmin. These results indicates that binding of single-chain urokinase to its receptor promotes its activity, retards its inhibition, and protects it from conversion to a two-chain form of the enzyme, a step that may precede its inactivation and clearance from cell surfaces. These results are consistent with a physiologic role for receptor-bound single-chain urokinase as a cellular plasminogen activator.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611676

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.

Authors:  A Poliakov; V Tkachuk; T Ovchinnikova; N Potapenko; S Bagryantsev; V Stepanova
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

2.  Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits.

Authors:  Andrey A Komissarov; Andrew P Mazar; Kathy Koenig; Anna K Kurdowska; Steven Idell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-08-07       Impact factor: 5.464

3.  Nebulization of Single-Chain Tissue-Type and Single-Chain Urokinase Plasminogen Activator for Treatment of Inhalational Smoke-Induced Acute Lung Injury.

Authors:  Soraya Hengsawas Surasarang; Sawittree Sahakijpijarn; Galina Florova; Andrey A Komissarov; Christina L Nelson; Enkhbaatar Perenlei; Satoshi Fukuda; Marla R Wolfson; Thomas H Shaffer; Steven Idell; Robert O Williams
Journal:  J Drug Deliv Sci Technol       Date:  2018-04-30       Impact factor: 3.981

4.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

5.  uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.

Authors:  William M Armstead; Douglas B Cines; Khalil H Bdeir; Yasmina Bdeir; Sherman C Stein; Abd Al-Roof Higazi
Journal:  J Cereb Blood Flow Metab       Date:  2008-12-03       Impact factor: 6.200

6.  Immunomodulatory effects of plasminogen activators on hepatic fibrogenesis.

Authors:  A A Higazi; M El-Haj; A Melhem; A Horani; O Pappo; C E Alvarez; N Muhanna; S L Friedman; R Safadi
Journal:  Clin Exp Immunol       Date:  2008-02-14       Impact factor: 4.330

7.  Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.

Authors:  Juan-Carlos Murciano; Abd Al-Roof Higazi; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2009-07-16       Impact factor: 9.776

8.  uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK.

Authors:  William M Armstead; Douglas B Cines; Khalil Bdeir; Irina Kulikovskaya; Sherman C Stein; Abd Al-Roof Higazi
Journal:  Brain Res       Date:  2008-07-08       Impact factor: 3.252

9.  Urokinase plasminogen activator impairs SNP and PGE2 cerebrovasodilation after brain injury through activation of LRP and ERK MAPK.

Authors:  William M Armstead; Amy J Christine; Abd Al-Roof Higazi; Douglas B Cines
Journal:  J Neurotrauma       Date:  2008-11       Impact factor: 5.269

10.  Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia.

Authors:  J Willis Kiessling; Douglas B Cines; Abd Al-Roof Higazi; William M Armstead
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-01-23       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.